よむ、つかう、まなぶ。
資料5-2 Ⅳ-197 イリノテカン塩酸塩水和物［746KB］ (30 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00047.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第69回 9／4）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；IV-197
5)
Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL.
Phase II study of irinotecan and temozolomide in children with relapsed or refractory
neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011;29(2):208-13.
6)
Moreno L, Waston R, Owens C, Couanet DV, Gambart M, Castel V, et al. Bevacizumab,
Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory
Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. J Clin
Oncol.2024;42(10):1135-45.
7)
Mody R, Yu AL, Naranjo A, et al. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in
Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology
Group. Journal of clinical oncology: official journal of the American Society of Clinical
Oncology 2020;38:2160-9.
8)
Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, Varo A,
Gorostegui M, Castañeda A, Garraus M, Lopez-Miralles S, Mora J. Early Salvage
Chemo-Immunotherapy with Irinotecan,Temozolomide and Naxitamab Plus GM-CSF (HITS) for
Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for
Long-Term Outcomes. Cancers. 2023;15:4837.
9)
CHILDREN’S CANCER AND LEUKAEMIA GROUP (CCLG) NEUROBLASTOMA
SPECIAL INTEREST GROUP. Options for the Treatment of Patients with Relapsed/Progressive
High-Risk Neuroblastoma.Ver3.0 Nov ,2017.
10) Kushner BH, Kramer K, Modak S, Cheung NKV. Irinotecan plus temozolomide for Relapsed or
refractory neuroblastoma. J Clin Oncol. 2006;24(33):5271-6.
11) Treatments for recurrent neuroblastoma（Last medical review: January 2020） Canadian Cancer
Society.
12) Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, et al. Irinotecan and
temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide
for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre,
open-label, randomised, controlled, phase 2 trial. Lancet Oncol.2024;25(7):922-32.
13) 大戸 佑二, 設楽 利二, 成相 宏樹, 鹿子生 祥子, 棗田 とも, 谷内 真由美, et al.イリノテ
カン＋テモゾロミド療法により 多発骨転移の改善をみた再発神経芽腫の 1 例. 小児が
ん.2008;45(3):297-301.
14) 中村 こずえ, 椿 英晴, 加賀 文彩, 荻田 佳織, 佐藤 恭弘, 越智 琢司, et al. 神経芽腫の
中枢神経再発に対するイリノテカン＋テモゾロミド療法の効果.小児が
ん.2012;49(4);507-11.
15) Yuichi Kodama, Yasuhiro Okamoto, Takanari Abematsu, Shunsuke Nakagawa, Koichiro
Kurauchi, Takuro Nishikawa, Takayuki Tanabe, Yuichi Shinkoda, Yoshifumi Kawano. Irinotecan
and temozolomide for refractory solid tumors in children. The Japanese Journal of Pediatric
Hematology/Oncology 2015;52(5):405–8.
26
5)
Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL.
Phase II study of irinotecan and temozolomide in children with relapsed or refractory
neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011;29(2):208-13.
6)
Moreno L, Waston R, Owens C, Couanet DV, Gambart M, Castel V, et al. Bevacizumab,
Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory
Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. J Clin
Oncol.2024;42(10):1135-45.
7)
Mody R, Yu AL, Naranjo A, et al. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in
Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology
Group. Journal of clinical oncology: official journal of the American Society of Clinical
Oncology 2020;38:2160-9.
8)
Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, Varo A,
Gorostegui M, Castañeda A, Garraus M, Lopez-Miralles S, Mora J. Early Salvage
Chemo-Immunotherapy with Irinotecan,Temozolomide and Naxitamab Plus GM-CSF (HITS) for
Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for
Long-Term Outcomes. Cancers. 2023;15:4837.
9)
CHILDREN’S CANCER AND LEUKAEMIA GROUP (CCLG) NEUROBLASTOMA
SPECIAL INTEREST GROUP. Options for the Treatment of Patients with Relapsed/Progressive
High-Risk Neuroblastoma.Ver3.0 Nov ,2017.
10) Kushner BH, Kramer K, Modak S, Cheung NKV. Irinotecan plus temozolomide for Relapsed or
refractory neuroblastoma. J Clin Oncol. 2006;24(33):5271-6.
11) Treatments for recurrent neuroblastoma（Last medical review: January 2020） Canadian Cancer
Society.
12) Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, et al. Irinotecan and
temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide
for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre,
open-label, randomised, controlled, phase 2 trial. Lancet Oncol.2024;25(7):922-32.
13) 大戸 佑二, 設楽 利二, 成相 宏樹, 鹿子生 祥子, 棗田 とも, 谷内 真由美, et al.イリノテ
カン＋テモゾロミド療法により 多発骨転移の改善をみた再発神経芽腫の 1 例. 小児が
ん.2008;45(3):297-301.
14) 中村 こずえ, 椿 英晴, 加賀 文彩, 荻田 佳織, 佐藤 恭弘, 越智 琢司, et al. 神経芽腫の
中枢神経再発に対するイリノテカン＋テモゾロミド療法の効果.小児が
ん.2012;49(4);507-11.
15) Yuichi Kodama, Yasuhiro Okamoto, Takanari Abematsu, Shunsuke Nakagawa, Koichiro
Kurauchi, Takuro Nishikawa, Takayuki Tanabe, Yuichi Shinkoda, Yoshifumi Kawano. Irinotecan
and temozolomide for refractory solid tumors in children. The Japanese Journal of Pediatric
Hematology/Oncology 2015;52(5):405–8.
26